Figure 2.
![Platelet count recovery stratified by disease [romiplostim-treated MM (A) and lymphoma (B)] vs retrospective data. Solid lines represent the median platelet count (× 109/L) with 95% CIs (blue = romiplostim study patients; red = retrospective data).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/7/8/10.1182_bloodadvances.2022007838/2/blooda_adv-2022-007838-gr2.jpeg?Expires=1724952202&Signature=i8amZ4Fsi75WbBW9Ob9UTZaSt2FepesQ2wmYwWWbvz5TDOLDUxCLTRw-DDcbR7vGrel9JhJE-EfZeBKBougdLo2iZkokhgDMqJa1kbEwSE1J9vQZsPfULX9vG55v3INKgXFNhfDA7RYNIpqU3YgSCirsXOuogxgx7swOlU2Kt--GwkpVy0ynB~3dmNzrPFTTc-t8qoZ0rM7VTRvmdHjr1U23mlkHoV7z7VIi-Jkb9Ns7uRUCYg5Mn-u1z9tZ9b5reokJ4~KHbCAfSxpWMcd-e3U9AmSLKz36fcpZ3axNkozPtFJfDpxrYOBpay4vm5h7hfivPsqUTqL6WjENvD2XWA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Platelet count recovery stratified by disease [romiplostim-treated MM (A) and lymphoma (B)] vs retrospective data. Solid lines represent the median platelet count (× 109/L) with 95% CIs (blue = romiplostim study patients; red = retrospective data).
